Technical Analysis for OCUL - Ocular Therapeutix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Down |
| Historical OCUL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | -2.67% | |
| Slingshot Bearish | Bearish Swing Setup | -2.67% | |
| NR7 | Range Contraction | -2.67% | |
| 200 DMA Support | Bullish | -4.95% | |
| MACD Bearish Signal Line Cross | Bearish | -1.19% | |
| 20 DMA Resistance | Bearish | -7.88% | |
| Calm After Storm | Range Contraction | -7.88% | |
| Inside Day | Range Contraction | -7.88% | |
| Fell Below 20 DMA | Bearish | -5.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | about 17 hours ago |
| Down 3% | about 17 hours ago |
| Fell Below 200 DMA | about 17 hours ago |
| 200 DMA Support | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/05/2021
Ocular Therapeutix, Inc. Description
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Pain Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Disease Incision Cataract Eye Diseases Treatment Of Glaucoma Cornea Incisions Allergic Conjunctivitis Cataract Surgery Allergology Ocular Hypertension Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.3 |
| 52 Week Low | 5.85 |
| Average Volume | 1,086,874 |
| 200-Day Moving Average | 14.95 |
| 50-Day Moving Average | 17.25 |
| 20-Day Moving Average | 16.10 |
| 10-Day Moving Average | 16.29 |
| Average True Range | 1.24 |
| ADX | 20.02 |
| +DI | 17.46 |
| -DI | 31.56 |
| Chandelier Exit (Long, 3 ATRs ) | 16.07 |
| Chandelier Exit (Short, 3 ATRs ) | 17.89 |
| Upper Bollinger Band | 18.35 |
| Lower Bollinger Band | 13.85 |
| Percent B (%b) | 0.25 |
| BandWidth | 27.95 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.30 |
| MACD Histogram | -0.1076 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.01 | ||||
| Resistance 3 (R3) | 16.98 | 16.27 | 16.67 | ||
| Resistance 2 (R2) | 16.27 | 15.75 | 16.29 | 16.56 | |
| Resistance 1 (R1) | 15.62 | 15.43 | 15.27 | 15.65 | 16.44 |
| Pivot Point | 14.91 | 14.91 | 14.73 | 14.93 | 14.91 |
| Support 1 (S1) | 14.26 | 14.39 | 13.91 | 14.29 | 13.50 |
| Support 2 (S2) | 13.55 | 14.07 | 13.57 | 13.38 | |
| Support 3 (S3) | 12.90 | 13.55 | 13.27 | ||
| Support 4 (S4) | 12.93 |
